Diminished KMT2D levels lead to increased production and release of activin A, which activates the noncanonical p38 MAPK-dependent pathway and drives the epithelial–mesenchymal transition in cancer cells to promote invasiveness (Figure 2). Here, KMT2D is linked to cancer.